PDCD1 and neoplasm: As EL4 tumour-bearing mice are unresponsive to anti-PD-1 alone, we examined the ability of APOMAB-immunoPET to detect tumour response to ICB using mice bearing syngeneic MC38 colon carcinoma, which has been shown to respond to anti-PD-1 therapy [32, 33].